The cardiovascular health benefits of longchain n-3 @entity1474 ( @entity5204 ) have been reported to exert at several different cellular control mechanisms. These include, effects on lipoprotein metabolism, haemostatic function, platelet/vessel wall interactions, anti-arrhythmic actions and also inhibition of proliferation of smooth muscle cells and therefore growth of the @entity731 . Fish oil feeding has also been found to result in moderate @entity551 and to modify vascular neuroeffector mechanisms. The majority of such cardiovascular benefits of n-3 @entity5204 are likely to be mediated in the vascular wall and at the vascular endothelium level, since this monolayer of cells plays a central role in the regulation and maintenance of cardiovascular homeostasis and function. While these processes include endothelium-derived vasorelaxant and vasoconstrictor compounds, the vascular endothelium also plays host to many receptors, binding proteins, transporters and signalling mechanisms. Accordingly, @entity409 , which underlies many @entity65 conditions, can trigger acute vascular events including @entity2553 , @entity715 or @entity256 leading to ischaemia. The longchain n-3 @entity5204 have been reported to possess several properties that may positively influence vascular function. These include favourable mediator profiles ( @entity842 , @entity1813 ) that influence vascular reactivity, change in vascular tone via actions on selective ion channels, and maintenance of vascular integrity. In addition to direct effects on contractility, n-3 @entity5204 may affect vascular function, and the process of atherogenesis, via inhibition of vascular smooth muscle cell proliferation at the gene expression level, and by modifying expression of inflammatory cytokinesis and adhesion molecules. Collectively, these properties are consistent with pleiotropic actions of longchain n-3 @entity5204 , and may explain the beneficial cardiovascular protection of this family of @entity1718 that have been clearly evident through epidemiological data as well from more recent large-scale clinical trials.

Longchain n-3 XXXX and blood vessel function.

@entity5204 :: ('CHEBI:26208', 'Chemical') :: ['PUFAs'] @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids'] @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction'] @entity2553 :: ('MESH:D020301', 'Disease') :: ['vasospasm'] @entity1474 :: ('MESH:D005231', 'Chemical') :: ['polyunsaturated fatty acids'] @entity256 :: ('MESH:D023903', 'Disease') :: ['restenosis'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic plaque'] @entity1813 :: ('MESH:D015777', 'Chemical') :: ['eicosanoids'] @entity551 :: ('MESH:D007022', 'Disease') :: ['reductions in blood pressure'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']
@entity1474 :: (MESH:D005231,Chemical) :: ['polyunsaturated fatty acids']
